EGFR and neoplasm: Although the treatment of HNSC has been improved by immunotherapies as well as epidermal growth factor receptor (EGFR)-based targeted therapies, the prognosis of HNSC patients still remains poor, with about 50% of patients suffered from acquired therapies resistances or tumor metastasis due to unclear mechanisms [6–9].